Real demand
It displaces TENS units (weak efficacy) and opioid painkillers (addiction risk). Clinician endorsement, FDA clearance, and HSA/FSA eligibility give patients a reason to keep paying rather than try once.
Real-revenue cases
A pediatric ER doctor built FDA-cleared physical pain-relief devices and sells them direct-to-patient through HSA/FSA-eligible channels, at roughly $208K in monthly revenue.
01
It displaces TENS units (weak efficacy) and opioid painkillers (addiction risk). Clinician endorsement, FDA clearance, and HSA/FSA eligibility give patients a reason to keep paying rather than try once.
Patients and clinics buy the devices outright; HSA/FSA eligibility lets customers pay with pre-tax health account balances. Sales run through the company's Shopify store, Amazon, and clinic purchasing.
TENS electrical-stimulation units and post-surgical opioid painkillers.
02
Not specified; the founder only notes sales to patients and healthcare centers began in 2009.
03
For AI businesses: the transferable move is the reimbursement-plus-endorsement distribution logic — attach your AI tool to a budget line enterprises already have (training, compliance) and let credible practitioners do the education, which beats paid ads on acquisition cost.
04
Revenue basis · Founder self-reported, unaudited (see source page)
The $208K monthly figure is founder self-reported and unaudited, and doesn't reconcile with other ARR figures cited on the same source page (e.g., $2.5M ARR).
The 64% YoY growth lacks a stated base and period, so growth quality can't be assessed.
The HSA/FSA channel 'exploding' is qualitative only — no share or dollar figure given.